{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:26:45Z","timestamp":1779892005459,"version":"3.53.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40123-025-01164-5","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T08:19:55Z","timestamp":1751962795000},"page":"1773-1787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Trial Simulation in Diabetic Retinopathy: Insights from Patients and Site Staff"],"prefix":"10.1007","volume":"14","author":[{"given":"Stela","family":"Vujosevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Gunderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Burale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Moody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Stacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gliem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"1164_CR1","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41433-022-01989-5","volume":"36","author":"A Qasim","year":"2022","unstructured":"Qasim A, Devji T, Phillips MR, et al. Seeing the patient\u2019s perspective: a guide to patient-reported outcome measures and minimal important differences in ophthalmic research. Eye. 2022;36:1339\u201341. https:\/\/doi.org\/10.1038\/s41433-022-01989-5.","journal-title":"Eye"},{"key":"1164_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/bjophthalmol-2016-309955","volume":"101","author":"S Dean","year":"2017","unstructured":"Dean S, Mathers JM, Calvert M, et al. \u201cThe patient is speaking\u201d: discovering the patient voice in ophthalmology. Br J Ophthalmol. 2017;101:700\u20138. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-309955.","journal-title":"Br J Ophthalmol"},{"key":"1164_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.811855","volume":"8","author":"A Murphy","year":"2021","unstructured":"Murphy A, Bere N, Vamvakas S, Mavris M. The added value of patient engagement in early dialogue at EMA: scientific advice as a case study. Front Med (Lausanne). 2021;8:811855. https:\/\/doi.org\/10.3389\/fmed.2021.811855.","journal-title":"Front Med (Lausanne)"},{"key":"1164_CR4","unstructured":"U.S. Food & Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. 2018. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input. Accessed 10 July 2024."},{"key":"1164_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40290-022-00458-4","volume":"37","author":"SD Faulkner","year":"2023","unstructured":"Faulkner SD, Somers F, Boudes M, Nafria B, Robinson P. Using patient perspectives to inform better clinical trial design and conduct: current trends and future directions. Pharm Med. 2023;37:129\u201338. https:\/\/doi.org\/10.1007\/s40290-022-00458-4.","journal-title":"Pharm Med"},{"key":"1164_CR6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.jid.2019.02.028","volume":"139","author":"B Hefele","year":"2019","unstructured":"Hefele B, Langan SM, Pollins K, Gelfand JM. Engaging the patient\u2019s perspective in clinical trials research. J Investig Dermatol. 2019;139:1217\u201320. https:\/\/doi.org\/10.1016\/j.jid.2019.02.028.","journal-title":"J Investig Dermatol"},{"key":"1164_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-064159","volume":"13","author":"C Boisvert-Huneault","year":"2023","unstructured":"Boisvert-Huneault C, Trigos Herraez D, Pinter A, et al. Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study. BMJ Open. 2023;13:e064159. https:\/\/doi.org\/10.1136\/bmjopen-2022-064159.","journal-title":"BMJ Open"},{"key":"1164_CR8","doi-asserted-by":"publisher","first-page":"00602-2022","DOI":"10.1183\/23120541.00602-2022","volume":"9","author":"S Jones","year":"2023","unstructured":"Jones S, Flewett M, Flewett R, et al. Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations. ERJ Open Res. 2023;9:00602-2022. https:\/\/doi.org\/10.1183\/23120541.00602-2022.","journal-title":"ERJ Open Res."},{"key":"1164_CR9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2147\/PPA.S137416","volume":"11","author":"SS Lim","year":"2017","unstructured":"Lim SS, Kivitz AJ, McKinnell D, Pierson ME, O\u2019Brien FS. Simulating clinical trial visits yields patient insights into study design and recruitment. Patient Prefer Adher. 2017;11:1295\u2013307. https:\/\/doi.org\/10.2147\/PPA.S137416.","journal-title":"Patient Prefer Adher"},{"key":"1164_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"N Cheung","year":"2010","unstructured":"Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(09)62124-3.","journal-title":"Lancet"},{"key":"1164_CR11","unstructured":"Kanavos P, van den Aardweg S, Schurer W. Diabetes expenditure, burden of disease and management in 5 EU countries. LSE Health, London School of Economics. 2012. http:\/\/www.lse.ac.uk\/business-and-consultancy\/consulting\/assets\/documents\/diabetes-expenditure-burden-of-disease-and-management-in-5-eu-countries.pdf. Accessed 21 Aug 2024."},{"key":"1164_CR12","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221\u201334. https:\/\/doi.org\/10.1016\/S2214-109X(17)30393-5.","journal-title":"Lancet Glob Health"},{"key":"1164_CR13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2337\/dc15-2171","volume":"39","author":"JL Leasher","year":"2016","unstructured":"Leasher JL, Bourne RRA, Flaxman SR, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39:1643\u20139. https:\/\/doi.org\/10.2337\/dc15-2171.","journal-title":"Diabetes Care"},{"key":"1164_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41433-019-0652-3","volume":"34","author":"M Zhao","year":"2020","unstructured":"Zhao M, Sun Y, Jiang Y. Anti-VEGF therapy is not a magic bullet for diabetic retinopathy. Eye. 2020;34:609\u201310. https:\/\/doi.org\/10.1038\/s41433-019-0652-3.","journal-title":"Eye"},{"key":"1164_CR15","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","volume":"255","author":"P Lanzetta","year":"2017","unstructured":"Lanzetta P, Loewenstein A. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graef Arch Clin Exp Ophthalmol. 2017;255:1259\u201373. https:\/\/doi.org\/10.1007\/s00417-017-3647-4.","journal-title":"Graef Arch Clin Exp Ophthalmol"},{"key":"1164_CR16","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","volume":"125","author":"TY Wong","year":"2018","unstructured":"Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: The International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. Ophthalmology. 2018;125:1608\u201322. https:\/\/doi.org\/10.1016\/j.ophtha.2018.04.007.","journal-title":"Ophthalmology"},{"key":"1164_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1900\/RDS.2015.12.159","volume":"12","author":"AJ Jenkins","year":"2015","unstructured":"Jenkins AJ, Joglekar MV, Hardikar AA, Keech AC, O\u2019Neal DN, Januszewski AS. Biomarkers in diabetic retinopathy. Rev Diabet Stud. 2015;12:159\u201395. https:\/\/doi.org\/10.1900\/RDS.2015.12.159.","journal-title":"Rev Diabet Stud"},{"key":"1164_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/aos.12802","volume":"94","author":"O Segal","year":"2016","unstructured":"Segal O, Segal-Trivitz Y, Nemet AY, Cohen P, Geffen N, Mimouni M. Anxiety levels and perceived pain intensity during intravitreal injections. Acta Ophthalmol. 2016;94:203\u20134. https:\/\/doi.org\/10.1111\/aos.12802.","journal-title":"Acta Ophthalmol"},{"key":"1164_CR19","doi-asserted-by":"publisher","first-page":"939","DOI":"10.2147\/opth.S100168","volume":"10","author":"S Sivaprasad","year":"2016","unstructured":"Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939\u201346. https:\/\/doi.org\/10.2147\/opth.S100168.","journal-title":"Clin Ophthalmol"},{"key":"1164_CR20","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s12325-023-02447-8","volume":"40","author":"D Rofail","year":"2023","unstructured":"Rofail D, Sherman S, Hartford C, et al. Development and preliminary validation of an instrument to measure symptoms and impacts in patients with proliferative diabetic retinopathy. Adv Ther. 2023;40:1773\u201386. https:\/\/doi.org\/10.1007\/s12325-023-02447-8.","journal-title":"Adv Ther"},{"key":"1164_CR21","unstructured":"Nguyen QD, Jhaveri C, Habib MS. Presented at: Association for Research in Vision and Ophthalmology; 2024. Oral presentation 959."},{"key":"1164_CR22","unstructured":"Boehringer Ingelheim. Phase 2. Indication: diabetic retinopathy (DR). 2024. https:\/\/www.boehringer-ingelheim.com\/science\/human-pharma\/clinical-pipeline\/retinal-health\/bi-764524. Accessed 21 Aug 2024."},{"key":"1164_CR23","unstructured":"Boehringer Ingelheim. Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia. 2024. https:\/\/www.boehringer-ingelheim.com\/science-innovation\/human-health-innovation\/positive-results-diabetic-macular-ischemia-treatment. Accessed 21 Aug 2024."},{"key":"1164_CR24","doi-asserted-by":"publisher","unstructured":"Boehringer Ingelheim. Video shown to patients taking part in the diabetic retinopathy trial simulation. 2025. https:\/\/doi.org\/10.60915\/Boehringer-figshare.29221040.v1. Accessed 05 June 2025.","DOI":"10.60915\/Boehringer-figshare.29221040.v1"},{"key":"1164_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12886-018-0753-y","volume":"18","author":"D Acan","year":"2018","unstructured":"Acan D, Calan M, Er D, et al. The prevalence and systemic risk factors of diabetic macular edema: a cross-sectional study from Turkey. BMC Ophthalmol. 2018;18:91. https:\/\/doi.org\/10.1186\/s12886-018-0753-y.","journal-title":"BMC Ophthalmol"},{"key":"1164_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4738","volume":"363","author":"JC Crocker","year":"2018","unstructured":"Crocker JC, Ricci-Cabello I, Parker A, et al. Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. BMJ. 2018;363:k4738. https:\/\/doi.org\/10.1136\/bmj.k4738.","journal-title":"BMJ"},{"key":"1164_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1177\/2168479017716715","volume":"52","author":"B Levitan","year":"2018","unstructured":"Levitan B, Getz K, Eisenstein EL, et al. Assessing the financial value of patient engagement: a quantitative approach from CTTI\u2019s patient groups and clinical trials project. Ther Innov Regul Sci. 2018;52:220\u20139. https:\/\/doi.org\/10.1177\/2168479017716715.","journal-title":"Ther Innov Regul Sci"},{"key":"1164_CR28","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s11136-019-02165-1","volume":"28","author":"K Khoo","year":"2019","unstructured":"Khoo K, Man REK, Rees G, Gupta P, Lamoureux EL, Fenwick EK. The relationship between diabetic retinopathy and psychosocial functioning: a systematic review. Qual Life Res. 2019;28:2017\u201339. https:\/\/doi.org\/10.1007\/s11136-019-02165-1.","journal-title":"Qual Life Res"},{"key":"1164_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ajo.2023.07.005","volume":"256","author":"G Valluru","year":"2023","unstructured":"Valluru G, Costa A, Klawe J, Liu B, Deobhakta A, Ahmad S. Depression in individuals with diabetic retinopathy in the US National Health and Nutrition Examination Survey, 2005\u20132008. Am J Ophthalmol. 2023;256:63\u20139. https:\/\/doi.org\/10.1016\/j.ajo.2023.07.005.","journal-title":"Am J Ophthalmol"},{"key":"1164_CR30","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/jamaophthalmol.2017.2553","volume":"135","author":"JR Willis","year":"2017","unstructured":"Willis JR, Doan QV, Gleeson M, et al. Vision-related functional burden of diabetic retinopathy across severity levels in the United States. JAMA Ophthalmol. 2017;135:926\u201332. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.2553.","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01164-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01164-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01164-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T17:29:30Z","timestamp":1752773370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01164-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1164"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01164-5","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stela Vujosevic: AbbVie, Inc., Alimera, Apellis Pharmaceuticals, Inc., Bayer, Boehringer Ingelheim, Novartis, RetinAI, Roche, Zeiss (consultancy fees). Ivana Gunderson: 4D Molecular Therapeutics, Inc., AbbVie, Inc., Alexion Pharmaceuticals, Inc., Annexon Biosciences, Apellis Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG., Cognition Therapeutics, Inc., Eyepoint Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd, Genentech, Inc., IMA Group, Janssen Research & Development, LLC, Kyowa Kirin Co., Ltd., Stealth BioTherapeutics, Inc., The Lowy Medical Research Institute, Ltd, (financial support); Boehringer Ingelheim Pharma GmbH & Co. KG, F. Hoffman-La Roche Ltd, Ora, Inc (consultancy fees); Austin Clinical Research, LLC, Gunderson Research Consulting, LLC (personal financial interest). Asma Burale: Boehringer Ingelheim (consultancy fees). Ben Moody: None. Rebecca C. Stacy: Boehringer Ingelheim (employee). Martin Gliem: Boehringer Ingelheim International GmbH (employee).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Market research does not require Institutional Review Board (IRB) approval because it falls outside the remit of the governance arrangements for research ethics committees. The market research conducted was carried out to understand behavior and opportunities and inform business decision-making. The project was conducted in line with local data protection laws and Market Research Society\u2019s Code of Conduct, including British Healthcare Business Intelligence Association, European Society for Opinion and Market Research, European Pharmaceutical Market Research Association, and other relevant national codes of practice. No clinical assessments were undertaken as part of the project which would then necessitate IRB approval. The participants were selected independently of the sponsor and consented to participating in the market research project in line with standard market research guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}